Cargando…

PREDICT Prostate, a useful tool in men with low- and intermediate-risk prostate cancer who are hesitant between conservative management and active treatment

Detalles Bibliográficos
Autores principales:	Devos, Gaëtan, Joniau, Steven
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7364577/ https://www.ncbi.nlm.nih.gov/pubmed/32669105 http://dx.doi.org/10.1186/s12916-020-01681-z

Ejemplares similares

Risk stratification tools in prostate cancer, where do we stand?
por: Clinckaert, Andries, et al.
Publicado: (2021)

Preclinical Models in Prostate Cancer: Resistance to AR Targeting Therapies in Prostate Cancer
por: Devlies, Wout, et al.
Publicado: (2021)

Penile metastasis in prostate cancer patients: Two case reports, surgical excision technique, and literature review
por: Landen, Lucas, et al.
Publicado: (2023)

Double trouble for prostate cancer: synergistic action of AR blockade and PARPi in non-HRR mutated patients
por: Giesen, Alexander, et al.
Publicado: (2023)

No significant difference in intermediate key outcomes in men with low- and intermediate-risk prostate cancer managed by active surveillance
por: Cyll, Karolina, et al.
Publicado: (2022)

What is the Need for Prostatic Biomarkers in Prostate Cancer Management?
por: Spahn, Martin, et al.
Publicado: (2015)

Clinical Actionability of the Genomic Landscape of Metastatic Castration Resistant Prostate Cancer
por: Devlies, Wout, et al.
Publicado: (2020)

MRI for managing intermediate & low risk prostate cancer
por: Padhani, Anwar R
Publicado: (2014)

Risk-prediction tools in prostate cancer: the challenge of tailoring
por: Morlacco, Alessandro, et al.
Publicado: (2016)

Comparison by Race of Conservative Management for Low-Risk and Intermediate-Risk Prostate Cancers in Veterans From 2004 to 2018
por: Parikh, Ravi B., et al.
Publicado: (2020)

FRI475 The Impact Of Suppression Of Androgen Signaling On Thyroid Hormone Homeostasis In Prostate Cancer Patients
por: David, Karel, et al.
Publicado: (2023)

Trends in Androgen Deprivation Use in Men With Intermediate-Risk Prostate Cancer Who Underwent Radiation Therapy
por: Agrawal, Vishesh, et al.
Publicado: (2022)

Metastasis-directed therapy in castration-refractory prostate cancer (MEDCARE): a non-randomized phase 2 trial
por: Berghen, Charlien, et al.
Publicado: (2020)

Reference range of serum prostate-specific antigen levels in Indian men
por: Mittal, Rama Devi
Publicado: (2014)

Distinct Genomic Alterations in Prostate Tumors from African American Men
por: Wang, Zhaoming
Publicado: (2015)

Association between a 17-gene genomic prostate score and multi-parametric prostate MRI in men with low and intermediate risk prostate cancer (PCa)
por: Leapman, Michael S., et al.
Publicado: (2017)

Are we progressing in prostate cancer management?
por: Patel, Hiten RH., et al.
Publicado: (2021)

Focal low-dose-rate prostate brachytherapy for low- and intermediate-risk prostate cancer
por: Kunogi, Hiroaki, et al.
Publicado: (2020)

Integrating phosphoproteomics into the clinical management of prostate cancer
por: Cheng, Larry C., et al.
Publicado: (2017)

Prognostic value of PTEN loss in men with conservatively managed localised prostate cancer
por: Cuzick, J, et al.
Publicado: (2013)

Can men with prostates sized 80 mL or larger be managed conservatively?
por: Lee, Alvin, et al.
Publicado: (2017)

MicroRNAs as clinical tools for diagnosis, prognosis, and therapy in prostate cancer
por: Ghamlouche, Fatima, et al.
Publicado: (2023)

Oncological Outcomes of Metastasis-Directed Therapy in Oligorecurrent Prostate Cancer Patients Following Radical Prostatectomy
por: Devos, Gaëtan, et al.
Publicado: (2020)

Commentary on “Clinical implications of endogenous testosterone density in prostate cancer progression in patients with favorable low and intermediate risk treated with radical prostatectomy”
por: Busetto, Gian Maria, et al.
Publicado: (2023)

Time to change the management of upper urinary tract urothelial carcinoma
por: Akand, Murat, et al.
Publicado: (2020)

The need for a personalized approach for prostate cancer management
por: Sedelaar, JP Michiel, et al.
Publicado: (2015)

Obesity and prostate cancer research
por: Van den Broeck, Thomas, et al.
Publicado: (2013)

The Within-Group Discrimination Ability of the Cancer of the Prostate Risk Assessment Score for Men with Intermediate-Risk Prostate Cancer
por: Kang, Ho Won, et al.
Publicado: (2017)

Management of prostate cancer in older men: recommendations of a working group of the International Society of Geriatric Oncology
por: Droz, Jean-Pierre, et al.
Publicado: (2010)

Ceramide in the prostate
por: Dent, Paul
Publicado: (2013)

Don’t Hesitate – Vaccinate!
por: Esernio-Jenssen, Debra, et al.
Publicado: (2020)

A novel DNA methylation score accurately predicts death from prostate cancer in men with low to intermediate clinical risk factors
por: Ahmad, Amar S., et al.
Publicado: (2016)

Comparison of Peri-operative and Early Oncological Outcomes of Robot-Assisted vs. Open Salvage Lymph Node Dissection in Recurrent Prostate Cancer
por: Devos, Gaëtan, et al.
Publicado: (2019)

Community Forums to Address Vaccine Hesitancy: A Useful Tool for Meeting the Needs of Diverse Communities
por: Palombi, Laura, et al.
Publicado: (2023)

Oligometastatic prostate cancer: Metastases-directed therapy?
por: Van Poppel, Hein, et al.
Publicado: (2016)

Commentary on “Solving the benign prostatic hyperplasia puzzle”
por: Thomas, Dominique, et al.
Publicado: (2018)

Prostate biopsy for elevated prostate specific antigen (PSA) – Indian perspective
por: Ragavan, N.
Publicado: (2014)

Monkeypox claims new victims: the outbreak in men who have sex with men
por: Liu, Xiaoning, et al.
Publicado: (2022)

Extended lymph node dissection for intermediate and high-risk prostate cancer: do we have all the evidence?
por: Ghazi, Ahmed
Publicado: (2015)

Rational and irrational vaccine hesitancy
por: Green, Manfred S.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_nj9k90re1f8e313f7de6hd70po